Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease.

Bislenghi G., Wolthuis A., Van Assche G., Vermeire S., Ferrante M., D'Hoore A.

Randomized Controlled Trial on Chronic Inflammation, Autoimmune Research, published in Expert Opin Biol Ther (2019) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Expert Opin Biol Ther (2019)
Country
England
Reported sample size
—
Source database
PubMed
PMID
31121104
DOI
10.1080/14712598.2019.1623876

Abstract (original English)

Introduction : Given the well-documented difficulty to treat perianal fistulizing Crohn's disease (pCD), with 40% of patients experiencing recurrence even after reiterative surgery and advanced medical therapy, research in this field has focused on the role of mesenchymal stem cells (MSC). Areas covered : The aim of this article is to furnish an overview of the pathogenetic mechanisms, clinical applications and evidences for the use of MSC for pCD with particular focus on adipose-derived allogenic MSC including darvadstrocel. Expert Opinion : The effect of MSC on fistula healing is probably mediated by their anti-inflammatory properties more than by their ability to engraft and trans-differentiate in the healthy tissue. A holistic treatment of pCD, addressing different pathophysiological factors, may represent the key for an improvement in the healing rate. In this setting, MSC might play a role as 'augmentation' therapy in combination with more conventional treatments. Whether MSC have benefit in non-complex fistula in biological naïve patients, in complex fistula with many tracts and/or in rectovaginal fistulas, are unexplored fields that need further investigation. A central registry of pCD patients undergoing treatment with MSC should be created in order to elucidate the efficacy, safety and costs of stem cells treatment on long term follow up.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adipose TissueCrohn DiseaseDouble-Blind MethodHumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsPainRectal FistulaTransplantation, HomologousTreatment Outcome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research